


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula (I):



wherein

ring A is an azetidine ring ~~which may have further substituent(s)~~,

X is oxygen, sulfur or nitrogen ~~which may have substituent(s)~~,

R¹ and R², R³ and R⁴ are each independently C₁₋₈ alkyl ~~which may have substituent(s)~~ or a benzene ring which may have substituent(s),

R³ is hydrocarbon group which may have substituent(s),

R⁴ is hydrogen,

~~hydrogen, a hydrocarbon group which may have substituent(s), SO₂R⁵ or a heterocyclic ring which may have substituent(s),~~


R⁵ is a hydrocarbon group which may have substituent(s),

R¹ and R², and R³ and R⁴ may be taken together with the adjacent nitrogen atom to form an N-containing heterocyclic ~~a piperidine, pyrrolidine, morpholine, piperazine, indoline, tetrahydroquinoline or tetrahydroisoquinoline~~ ring group which may have further substituent(s), or

a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof.

2-3. (Cancelled)

4. (Currently Amended) The compound according to claim 1, which is a compound of the formula (I-1):



wherein

R¹ is a benzene ring which may have substituent(s), and

R² is C₁₋₈ alkyl which may have substituent(s) or a benzene ring which may have substituent(s), are each independently hydrogen, a hydrocarbon group which may have substituent(s), SO₂R⁵ or a heterocyclic ring group which may have substituent(s),

R⁵ is a hydrocarbon group which may have substituent(s),

R⁴ and R² are taken together with the adjacent nitrogen atom to form an N-containing heterocyclic ring group which may have substituent(s),

R¹¹ is any arbitrary substituent(s), and

n is 0 or an integer of 1-5, with the proviso that when n is 2 or more, the plural R¹¹'s may be the same or different.

5. (Currently Amended) The compound according to claim 1 wherein R¹ and R² are taken together with the adjacent nitrogen atom to form a piperidine, pyrrolidine, morpholine, piperazine, indoline, tetrahydroquinoline and tetrahydroisoquinoline an N-containing heterocyclic ring group which may further have substituent(s).

6-7. (Cancelled)

8. (Original) The compound according to claim 1, which is selected from the group consisting of N-(3,5-dichlorophenyl)-3-(4-phenylpiperidin-1-yl)azetidine-1-carboxamide, 3-(2,3-dihydro-1H-indol-1-yl)-N-[3-(trifluoromethyl)phenyl]azetidine-1-carboxamide, N-(3,5-dichlorophenyl)-3-(2,3-dihydro-1H-indol-1-yl)azetidine-1-carboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3-(2,3-dihydro-1H-indol-1-yl)azetidine-1-carboxamide, 3-(2,3-dihydro-1H-indol-1-yl)-N-(3-phenoxyphenyl)azetidine-1-carboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3-[methyl(phenyl)amino]azetidine-1-carboxamide and N-[3,5-bis(trifluoromethyl)phenyl]-3-[ethyl(phenyl)amino]azetidine-1-carboxamide.

9. (Currently Amended) A pharmaceutical composition comprising the compound of the formula (I), or a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof described in claim 1, together with a pharmaceutically acceptable carrier.

10-19. (Cancelled)